DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20201574

A profile of cases of gestational trophoblastic neoplasia at a tertiary care centre in South India

Rakesh M. P., Kalaichelvi K., Govind Gangadharan, Vishnu Sreedath

Abstract


Background: Gestational trophoblastic disease (GTD) comprises a spectrum of diseases ranging from molar pregnancy to malignant gestational trophoblastic neoplasia (GTN). GTN are highly chemo-sensitive tumours which are treated as per FIGO risk stratification. The rarity of the disease limits the evidence regarding the disease to case series and reports. The objective of this study was to study incidence, baseline characteristics of patients and clinical outcome of GTN patients treated at this centre.

Methods: This is a retrospective descriptive study based on medical records of patients of GTD who were registered in department of medical oncology, from January 2015 to December 2018 (4 years). GTN was diagnosed based on serum beta HCG values. Their baseline characteristics, risk score, serum β HCG levels, and treatment regimens were investigated. The incidence of GTD and response to treatment were analysed.

Results: Out of 211 GTD patients, 56 developed GTN. The incidence was 3.4 per 10000 deliveries. Low risk cases (n=38) were treated with methotrexate and actinomycin in first line while high risk cases received EMACO and EP followed by EMACO as the first line. A cure rate of 100% for low risk cases and 94.4% (n=17) for high risk cases were recorded. Resistance to MTX was 32.3% while EMACO was resistant in 46.6% as first line. Neutropenia and alopecia were the most common treatment related adverse events. Predictors of resistance to single agent in low risk GTN include higher pre-treatment βHCG values and higher risk scores.

Conclusions: GTN exemplifies a rare, highly aggressive but curable malignancy. Serum βHCG is the most reliable diagnostic as well as prognostic marker in management of GTD. EMACO is the preferred regimen for high risk GTN. FIGO staging and risk stratification help in individualizing the treatment to ensure maximum response to therapy thus making GTN a curable malignancy.


Keywords


Choriocarcinoma, EMACO, FIGO, Gestational trophoblastic neoplasia, Gestational trophoblastic disease, βHCG

Full Text:

PDF

References


Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376(9742):717-29.

Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol. 2003;4(11):670-8.

Aminimoghaddam S, Yarandi F, Nejadsalami F, Taftachi F, Noor Bakhsh F, Mahmoudzadeh F. Human chorionic gonadotrophin as an indicator of persistent gestational trophoblastic neoplasia. Med J Islam Repub Iran. 2014;28:44.

Berkowitz RS, Goldstein DP. Chorionic Tumors. N Engl J Med. 1996;335(23):1740-8.

Homesley HD. Single-agent therapy for nonmetastatic and low-risk gestational trophoblastic disease. J Reprod Med. 1998;43(1):69-74.

PDQ Adult Treatment Editorial Board PATE. Gestational Trophoblastic Disease Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. National Cancer Institute (US); 2002. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26389414. Accessed on 10th June 2019.

FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2009;105(1):3-4.

Loukovaara M, Pukkala E, Lehtovirta P, Leminen A. Epidemiology of hydatidiform mole in Finland, 1975 to 2001. Eur J Gynaecol Oncol. 2005;26(2):207-8.

Garner EIO, Goldstein DP, Feltmate CM, Berkowitz RS. Gestational trophoblastic disease. Clin Obstet Gynecol. 2007;50(1):112-2.

Lakra P, Sangwan V, Siwach S, Kansal R, Mahendru R, Sharma A. Outcome of gestational trophoblastic disease in a rural tertiary centre of Haryana, India. Int J Reprod Contraception, Obstet Gynecol. 2016;6(1):271.

Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203(6):531.

Horowitz NS, Goldstein DP, Berkowitz RS. Management of gestational trophoblastic neoplasia. Semin Oncol. 2009;36(2):181-9.

Shrivastava S, Kataki A, Deka P, Bhuyan C, Barmon D, Bhargav S. Gestational trophoblastic neoplasia: A 6-year retrospective study. South Asian J Cancer. 2014;3(1):33.

Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. In: Alazzam M, editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley and Sons, Ltd; 2012:CD008891.

Alazzam M, Tidy J, Bw H, Osborne R, Ta L. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Review. 2014;7.

Mousavi AS, Zamani A, Khorasanizadeh F, Gilani MM, Zendehdel K. Resistance to single-agent chemotherapy and its risk factors in low-risk gestational trophoblastic neoplasms. J Obstet Gynaecol Res. 201;41(5):776-83.

Homesley HD, Blessing JA, Schlaerth J, Rettenmaier M, Major FJ. Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: a gynecologic oncology group study. Gynecol Oncol. 1990;39(3):305-8.

Homesley HD, Blessing JA, Rettenmaier M, Capizzi RL, Major FJ, Twiggs LB. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet Gynecol. 1988;72(3 Pt 1):413-8.

Schink JC, III JRL. Gestational trophoblastic disease: Molar pregnancy and gestational trophoblastic neoplasia. Wolters Kluwer Health; 2013:886-908.

Ross GT, Goldstein DP, Hertz R, Lipsett MB, Odell WD. Sequential use of methotrexate and actinomycin d in the treatment of metastatic choriocarcinoma and related trophoblastic diseases in women. Am J Obstet Gynecol. 1965;93:223-9.

Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. Hematol Oncol Clin North Am. 2012;26(1):111-31.

Khan F, Everard J, Ahmed S, Coleman RE, Aitken M, Hancock BW. Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. Br J Cancer. 2003;89(12):2197-201.

McNeish IA, Strickland S, Holden L, Rustin GJS, Foskett M, Seckl MJ, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol. 2002;20(7):1838-44.

Mutch DG, Soper JT, Babcock CJ, Clarke-Pearson DL, Hammond CB. Recurrent gestational trophoblastic disease. Experience of the southeastern regional trophoblastic disease center. Cancer. 1990;66(5):978-82.